X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Viridian intends to use the proceeds to further its clinical development programs, including VRDN-001, a differentiated monoclonal antibody targeting IGF-1R, a clinically and commercially validated target for the treatment of thyroid eye disease.
Lead Product(s): VRDN-001
Therapeutic Area: Immunology Product Name: VRDN-001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 17, 2024
Details:
VRDN-003 is a monoclonal antibody that acts as a full antagonist of IGF-1R, a clinically and commercially validated target for TED. It is under phase 1 clinical development for the treatment of Thyroid Eye Disease (TED).
Lead Product(s): VRDN-003
Therapeutic Area: Immunology Product Name: VRDN-003
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The financing will be used to expand Viridian’s preclinical portfolio of FcRn inhibitors designed to deliver next generation treatments for patients suffering from antibody-mediated autoimmune diseases including VRDN-001, for patients with TED.
Lead Product(s): VRDN-001
Therapeutic Area: Immunology Product Name: VRDN-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fairmount Funds
Deal Size: $185.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 30, 2023
Details:
As part of the agreement, Ypsomed will customize and supply YpsoMate 2.25 patient-administered delivery devices to support Viridian’s development of investigational subcutaneous therapy candidate VRDN-001, for the treatment of thyroid eye disease (TED).
Lead Product(s): VRDN-001
Therapeutic Area: Immunology Product Name: VRDN-001
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Ypsomed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 26, 2023
Details:
VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED).
Lead Product(s): VRDN-001
Therapeutic Area: Immunology Product Name: VRDN-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED).
Lead Product(s): VRDN-001
Therapeutic Area: Immunology Product Name: VRDN-001
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2023
Details:
Viridian’s lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED).
Lead Product(s): ZB001
Therapeutic Area: Immunology Product Name: VRDN-001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
VRDN-001 is a monoclonal antibody that binds and blocks the IGF-1R signaling pathway with sub-nanomolar affinity. This mechanism of action is clinically and commercially validated for the treatment of TED.
Lead Product(s): ZB001
Therapeutic Area: Immunology Product Name: VRDN-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED).
Lead Product(s): VRDN-001
Therapeutic Area: Immunology Product Name: VRDN-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Viridian intends to use the proceeds from the underwritten public offering to further its clinical development programs including VRDN-001, as well as for working capital and general corporate purposes.
Lead Product(s): VRDN-001
Therapeutic Area: Immunology Product Name: VRDN-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $40.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
